Mitigating Mycoplasma Contamination: The Importance of Vigilance in Aseptic Processing
With the rapid development of biologics produced via cell substrates, it is paramount to keep on top of your aseptic procedures as well as routine testing to ensure your production batch isn’t botched.
What is Mycoplasma contamination and why does it matter?
Mycoplasma is the smallest prokaryotic organism that can live in cell-free culture media. Because they lack a cell wall, Mycoplasma is resistant to the most common antibiotics and they may pass through the conventional 0.2 μm filters used in cell culture, thus raising the potential for high contamination rates. Contamination can alter virtually every chemical and physical property of cells (depending on the contaminating species and the host type) causing them to yield unreliable results and perhaps unsafe biologicals, biopharmaceutical drugs or viral vaccines. In addition, Mycoplasma contamination can be present with no obvious change in the host culture making it very challenging to detect without dedicated testing. Whether your product is derived from cell substrates or is used by your customers in
cell culture, nobody wants mycoplasma in their facility.
What are the sources of Mycoplasma contamination?
There are over 200 Mycoplasma species identified originating from many sources ranging from soil to mammals, cells and insects.
Laboratory Personnel: Did you know that the majority of Mycoplasma contamination comes from people? Many Mycoplasma species are found on human skin and saliva (M. hominis, M. orale, and M. fermentans to name a few). A simple cough, sneeze, or even talking without a mask can inadvertently introduce Mycoplasma to surfaces you do not want it to be. Due to their extremely small size, Mycoplasma cannot be detected in routine Viable Environmental Monitoring of your cleanroom space or Biosafety Cabinet.
Raw Materials: Contaminated animal-derived supplements like fetal bovine serum and trypsin can lead to a full-scale contamination. Other reagents, such as plant-based serums, media, as well as feeder cells are also susceptible to contamination. Ensure you have a robust material receiving system that includes receipt of C of As, qualified vendors, and testing available to ensure all your raw materials are Mycoplasma free.
Equipment: Bioreactors, tubing, water baths, liquid nitrogen, even pipettes can harbor mycoplasma. These can all be considered potential culprits when testing and troubleshooting cultures. Ensure that all equipment is cleaned adequately and frequently. Adopt a robust and validated Cleaning and Disinfection Program for your cleanrooms and work surfaces.
What can I do to prevent Mycoplasma contamination at my site?
Strict adherence to Aseptic Technique procedures: It is absolutely essential to have well -trained, accountable personnel when working in aseptic conditions. Limit talking in controlled environments, never pipette by mouth, contain all work in a Biosafety Cabinet, and maintain strict adherence to gowning procedures. Working in closed systems is also recommended but remember, there will always be some form of human exposure to the raw materials and intermediates so stay vigilant and work carefully.
Trust your sources: Can you be sure that the companies that provide your primary components are doing their due diligence? Many media and supplement producers will test each batch of their products for Mycoplasma. If this data is not available or your Quality department requires third party testing, include routine testing for Mycoplasma as a requirement for releasing or green-tagging raw materials such as media, serum, or enzymes for your process.
Test Frequently: You may never know if you have a Mycoplasma contamination unless you test for it. Demonstrating that your product is free of adventitious agents (like Mycoplasma) is not only a good checkpoint in your process but it’s also a requirement by world-wide Regulatory agencies; there’s no way around it. Let’s take a look at the test points in a generic cell culture process where samples can be tested for Mycoplasma. The further upstream you perform your
testing, the earlier you know can mitigate any contamination to preserve labor and material costs.
There are several traditional test methods that follow USP, EU, and FDA Standards. This series of testing, known as direct and indirect culture methods, can be cumbersome due to the long incubation times and reliance on human observance for growth of the smallest free-living organism known to man. In the age of accelerated timelines to push product out the door, are you prepared to quarantine your raw materials or product for a month before resuming production? Time
is money, right?
The good news is that in 2007, the European Pharmacopeia accepted nucleic acid tests, such as real-time PCR, as an alternative method for traditional Mycoplasma detection after validation. PCR-based detection methods are highly sensitive and can provide rapid results, which allows researchers to respond quickly to isolate and eliminate contamination once it is detected in comparison to the time required using traditional techniques.
We at Infinity Laboratories, Inc. employ the MycoSEQ® mycoplasma detection system from Thermo Fisher Scientific which was designed to meet the guidance provided by the European Pharmacopoeia in 2007 of rapid-response tests. MycoSEQ, which utilizes quantitative PCR (qPCR) to detect more than 90 Mycoplasma species, can provide results in hours rather than 10 to 28 days. Using state-of-the-art automated equipment, Mycoplasma DNA is extracted by magnetic beads (also known as Solid Phase DNA Extraction) and then amplified in a thermal cycling machine. With the aid of SYBR® Green fluorescence technology, amplified DNA can be detected in real-time to determine whether Mycoplasma is present or absent in a sample.
About Infinity Laboratories
Infinity Laboratories was founded in 1991 on the bedrock principles of excellence, integrity, and quality. Today, the Company is a national chemical and microbiological testing laboratory servicing the pharmaceutical, biotechnology and medical device industries.
For more information about Infinity Laboratories, please visit infinitylaboratories.com
EY Announces Dan Henderson of Infinity Laboratories as an Entrepreneur Of The Year® 2020 Mountain Desert Region Award Finalist
Castle Rock, CO - September 9, 2020 - Ernst & Young LLP (EY US) announced that CEO/President Dan Henderson of Infinity Laboratories was named an Entrepreneur Of The Year® 2020 Mountain Desert Region Award finalist. Now in its 34th year, the Entrepreneur Of The Year...
CASTLE ROCK, CO - July 17, 2020 - Infinity Laboratories (infinitylaboratories.com) is excited to announce the acquisition of DYNALABS of St. Louis, MO. Founded in 2003, DYNALABS is a privately held Analytical Testing Laboratory that offers Lab Services, On Site...
Infinity Laboratories continues to grow scope and reach of services with the acquisition of MicroMed Laboratories
CASTLE ROCK, CO - June 24, 2020 - Infinity Laboratories (infinitylaboratories.com) is proud to announce the acquisition of MicroMed Laboratories of Petaluma, CA. Founded in 1999, MicroMed Laboratories is a publicly held Environmental Monitoring and Testing Services...